World Journal of Pharmacology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Number of total visits: 863535

Number of visits today: 527

Number of downloads: 556782

INDEXING/ABSTRACTING

MEMBERSHIP

BPG JOURNAL LIST

Open-Access Journal

Other Issues: Previous | Next | Latest | Archive | Download full issue 3 (329)

Contents Volume 11 Issue 3 November 28, 2022

Review

Controversial usages of kratom (Mitragyna speciosa): For good or for evil

Murtadha Basheer, Rana Khudhair Jasim, Gam Lay Harn

World J Pharmacol 11(3):16-26. Published online Nov 28, 2022. doi: 10.5497/wjp.v11.i3.16

Abstract (1162) | Core Tip (918) | Full Article (HTML) (20068) | Figures (1-1) (500) | Full Article (PDF)-3133K (360) | Audio-1027K (13) | Received: 07/15/2022 | Revised: 10/04/2022 | Accepted: 11/23/2022 | RCA | CrossRef | Google Scholar | Similar Articles (1) | Timeline of Article Publication (1) | Cite | (190) | (179) | (0) | (0) | (0) | (7) | (20989) | (1) | Open

Basic Study

Antidepressant-like potential of silymarin and silymarin-sertraline combination in mice: Highlighting effects on behaviour, oxidative stress, and neuroinflammation

Adejoke Yetunde Onaolapo, Hameed Sulaiman, Anthony Tope Olofinnade, Olakunle James Onaolapo

World J Pharmacol 11(3):27-47. Published online Nov 28, 2022. doi: 10.5497/wjp.v11.i3.27

Abstract (1028) | Core Tip (943) | Article Highlights (889) | Full Article (HTML) (5189) | Figures (1-9) (457) | Tables (1-2) (542) | Full Article (PDF)-10260K (363) | Audio-880K (69) | Received: 04/18/2022 | Revised: 06/05/2022 | Accepted: 10/19/2022 | RCA | CrossRef | Google Scholar | Similar Articles (308) | Timeline of Article Publication (2) | Cite | (221) | (224) | (0) | (0) | (0) | (14) | (6684) | (15) | Open

Write to the Help Desk

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.